MedTrace Logo

Eptinezumab in Participants With Episodic Cluster Headache

NCT04688775 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 231

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)

Conditions

  • Cluster Headache, Episodic

Interventions

DRUG

Eptinezumab

Eptinezumab - concentrate for solution for infusion, intravenously

DRUG

Placebo

Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-23
Primary Completion
2023-06-14
Completion
2023-10-05
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Georgia
  • Germany
  • Greece
  • Italy
  • Japan
  • Netherlands
  • Norway
  • Portugal
  • Russia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04688775 on ClinicalTrials.gov